News Center
US fertility clinics do not approve or reject a low-AMH patient on the AMH number alone. Approval usually hinges on three things the patient rarely sees: how one reproductive endocrinologist personally weighs your ovarian reserve against your age and history, whether the clinic's embryology lab is willing to commit resources to a cycle that may yield only one or two eggs, and what the physician decides not to volunteer during a 30-minute new-patient consult. Understanding that internal chain explains why the same lab result can produce opposite treatment plans at two clinics across the street from each other.
Anti-Müllerian hormone is a blood marker of the pool of small resting follicles, and most US clinics treat values roughly below 1.0 to 1.1 ng/mL as a sign of diminished ovarian reserve. That threshold itself has a documented pedigree: the so-called Bologna criteria, published by ESHRE in 2011, defined poor ovarian response using AMH below 0.5 to 1.1 ng/mL together with a low antral follicle count, and the POSEIDON classification (2018) later subdivided low-reserve patients by age and egg yield. Clinics in the United States borrow from these frameworks, but none of them is bound by them. The final gate is human.
Here is the part patients almost never learn. Before a low-reserve patient is formally "approved" for a stimulated IVF cycle, the plan typically passes through an internal review. At higher-volume centers this may be a weekly case conference where physicians present difficult profiles to colleagues; at smaller clinics it may be a single physician checking the proposed protocol against the lab's capacity and the clinic's own outcome statistics. The review is not primarily about safety. It is about whether the clinic believes the cycle has a reasonable chance of producing a usable blastocyst, because a cancelled or empty cycle damages the clinic's published success rates, which are reported to SART (the Society for Assisted Reproductive Technology) and audited against CDC data.
This creates the two-doctor problem. Take a 38-year-old with AMH 0.6 ng/mL, an antral follicle count of 4, and no prior cycles. Physician A reads that profile as "stimulate aggressively, accept whatever we get, one good blastocyst may be enough." Physician B reads the identical numbers as "the probability of a blastocyst per cycle is low enough that this patient will spend two years and multiple five-figure cycles to reach what a donor-egg path reaches in one." Both physicians are practicing within accepted standards of care. Neither is wrong on the medicine. The divergence comes from how each one weighs the same published probabilities against their own lab's performance and their own tolerance for a cycle that ends with nothing to transfer.
The practical consequence for you: a rejection from one clinic is frequently a statement about that clinic's internal economics and case-mix, not a verdict on your biology. Patients who are refused at a selective high-volume center are often approved at a clinic that routinely handles difficult responders, and the reverse is also true. Asking a clinic directly how many patients with an AMH under 1.0 ng/mL they stimulated last year, and what happened to them, is a legitimate question that cuts through this discretion faster than any AMH repeat test.
The mechanics matter because they tell you what to ask for. In a structured case conference, the presenting physician brings the patient's full workup: AMH, antral follicle count from ultrasound, day-2 or day-3 FSH and estradiol, age, BMI, prior response to stimulation if any, and the couple's goals. Colleagues then argue over protocol. For a low-reserve patient the live debate usually narrows to three decisions.
First, stimulation strategy. Options on the table include conventional high-dose gonadotropin protocols, micro-dose flare protocols, mild or minimal stimulation, and in some centers a dual-stimulation approach within one cycle. The evidence that any of these reliably increases live-birth rates in genuinely poor responders is thin; a Cochrane review of interventions for poor responders found no protocol that clearly improves live birth outcomes. What the conference is really deciding is which protocol the clinic's lab handles best and which one limits the worst-case scenario of zero mature eggs.
Second, the cancellation threshold. Every clinic has an implicit or explicit rule about when a cycle is cancelled before retrieval, commonly when fewer than two to three follicles are growing despite stimulation. Some clinics will proceed with a single follicle; others will cancel and convert. This number is a policy choice, and it varies more between clinics than almost any other parameter in the process. It is also the single most useful thing to ask about upfront, because it determines whether your money buys a retrieval or a cancelled cycle.
Third, batch versus solo. Some low-reserve patients are offered accumulated cycles: two or three mild stimulations with freezing of whatever embryos result, pooled for one genetic test and one transfer. Others are pushed into single conventional cycles. The choice depends heavily on whether the lab charges per batch or per cycle and whether the embryology team prefers working with pooled cohorts.
If a clinic resists putting its cancellation threshold and protocol rationale in writing before you pay, that resistance is itself information. Established centers such as CCRM Fertility, with its large centralized laboratory operation, or New Hope Fertility Center in Manhattan, which has historically built its model around mild stimulation for low-reserve and international patients, tend to have these policies formalized precisely because they handle so many difficult-responder cases. A clinic that improvises case by case leaves you exposed to the individual physician's mood on retrieval day.
This is the least visible gate in the entire approval chain, and it operates after you have already been accepted and paid. A stimulated cycle produces eggs; the lab then makes a series of resource-allocation decisions about those eggs, and with a low AMH the numbers involved are tiny. A typical average-responder cycle might yield 10 to 15 eggs. A low-AMH cycle might yield 2. Every downstream decision scales badly at that size.
Consider what the lab actually does. Each mature egg gets inseminated, either conventionally or with ICSI. Each resulting embryo is cultured, usually to the blastocyst stage around day 5 to 7, and may undergo preimplantation genetic testing. With 12 eggs, the lab spreads risk across many embryos and statistics smooth out. With 2 eggs, a single lab decision can determine the entire outcome of the cycle. Will the team culture both embryos to blastocyst, accepting that both may arrest, or freeze at day 3 as insurance? Will they recommend PGT on a cohort of one or two embryos, knowing the biopsy adds cost and a small risk while providing limited statistical power at that sample size? These calls are made by the embryology director and the physician together, and the patient is rarely consulted, because the consent forms were signed weeks earlier in generic language.
Lab capacity enters in a second, blunter way. High-volume labs run dozens of inseminations and hundreds of embryo cultures daily on fixed schedules. A cycle contributing one or two embryos still consumes culture dishes, incubator space, media, and embryologist time at nearly the same per-embryo fixed cost as a large cohort, but with far worse expected yield. Some labs absorb this willingly because difficult cases build their reputation and their SART-reported per-patient outcomes. Others steer low-yield patients toward milder, cheaper cycles or toward accumulated approaches, or quietly discourage them at the approval stage. The patient never sees this calculation. What she sees is a protocol, a price, and a calendar.
One verifiable check exists. CDC's ART reporting and SART's clinic-specific data include outcomes broken down by patient age and, in SART's patient-facing reports, by whether patients used their own eggs. A clinic whose own-egg success rates in the 38-to-40 and over-40 brackets sit well below the national range published by CDC may be filtering difficult cases out at the approval stage rather than treating them. A clinic whose numbers in those brackets are solid, relative to the national range, is probably one that accepts low-reserve patients and knows how to run their cycles. Neither number predicts your individual result, but the pattern tells you which kind of approval you are walking into.
The new-patient consult has a fixed clock, typically 20 to 40 minutes in US practice. Within it, the physician must take a history, review labs, propose a plan, and answer questions. Three subjects that determine whether your cycle ends in a transfer or in a loss tend to get compressed into a sentence or skipped entirely, not out of dishonesty, but because raising them unprompted feels pessimistic and eats time.
Most low-AMH patients first hear about cancellation thresholds when they are already stimulated and facing the decision emotionally and financially committed. The question that forces the issue early is concrete: "At what follicle count or estradiol level do you cancel a cycle, and if you cancel, what portion of what I paid carries over?" Some clinics credit the full monitoring and screening fees toward a future attempt; some charge cancellation fees; some convert to intrauterine insemination or a natural-cycle attempt. Getting the clinic's own number, in writing, before signing converts an invisible policy into a negotiable term.
Many patients assume the plan stated at consult, for instance a fresh transfer, is the plan. With low-reserve patients the conversion from fresh to frozen happens often: a thin lining, elevated progesterone on trigger day, or a solitary embryo that the team prefers to test before transferring all push the cycle into a freeze-all. The decision criteria are clinical and legitimate, but the patient who budgeted for one calendar window and one travel period, which applies to many international patients, discovers the change mid-cycle. Ask directly: "Under what specific conditions would this become a freeze-all cycle, and how much additional cost and time does that add?" A clinic that answers with specifics is one that has run these cycles many times before.
Physicians almost never volunteer the arithmetic that eventually drives this recommendation. A useful anchor comes from published population data: CDC's national ART reports show that per-cycle live-birth rates using a patient's own eggs fall steeply with age, dropping into the low single digits by the early-to-mid forties, and low AMH shifts the same curve earlier. A physician who has watched many low-reserve patients spend three cycles to reach one blastocyst will, at some internally calculated point, say the sentence "I think we should talk about donor eggs." Patients are often blindsided because nobody told them the clinic had been running that calculation since the first visit. You can preempt it. Ask the physician to state, in numbers, how many failed own-egg cycles they would want to see before recommending a change of direction, and whether their answer depends on your age, your embryo counts, or your finances. A physician who can answer that question with a number is one who has thought through your case rather than your AMH alone.
The approval chain runs on information asymmetry, and the countermeasure is a short list of specific questions posed before any money changes hands. Each one maps to a gate described above.
Two verification steps strengthen your position. Pull the clinic's own-egg outcome data for your age bracket from the SART or CDC reporting tools rather than from the clinic's marketing pages. And request that the protocol, cancellation threshold, and conversion criteria be summarized in the written plan or consent documents. Clinics with mature processes for difficult responders, among them high-volume groups like Shady Grove Fertility with its large network of regional offices, or Pinnacle Oregon in Portland, a practice dating to 1989 that has long handled a substantial share of difficult-responder cases, will produce such documentation routinely. Hesitation or vagueness on these points is a data point about the clinic, not about you.
Geography matters less than structure, but structure clusters in recognizable types of practice. Large multi-site groups with centralized laboratories, such as CCRM Fertility, which operates a consolidated lab model across its locations, tend to have formal case-review systems and written low-responder protocols because their volume forces standardization. Practices built historically around mild or minimal stimulation, such as New Hope Fertility Center in Manhattan and CNY Fertility in New York State, have spent years refining approaches that accept small egg cohorts rather than fighting them with high doses. Regional veterans with decades of difficult-case experience, for example Pinnacle Oregon in Portland or San Diego Fertility Center, founded in 1989, often combine individualized protocols with the case-conference culture described earlier. Specific success rates, cycle volumes, and pricing vary by location and change over time; the current figures published by each clinic and by SART and CDC are the only reliable reference.
The deeper point survives any clinic choice. A low AMH does not disqualify you from IVF in the United States, and no single blood value closes the door. What determines the outcome is a sequence of human judgments: one physician's reading of your file, one committee's tolerance for a low-yield cycle, one lab's willingness to invest in two eggs, and one conversation in which the hardest arithmetic is either stated plainly or withheld. Patients who learn to interrogate that chain before signing, rather than after, consistently end up with clearer plans, fewer surprise cancellations, and a much better sense of when persistence with their own eggs is a reasonable bet and when the honest answer lies in a different direction.
